Research
312 results
Name Type Target Compound Name Phase
Collaboration: Asklepios Hospital Barmbek; Bethesda Hospital Bergedorf; Agaplesion Diakonie Hospital; Amalie Sieveking Hospital; Asklepios Hospital Saint Georg; Institutional Funds of University Medical Center Hamburg-Eppendorf

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

SARS-CoV-2 genetic material — viral RNA N/A Pre-Clinical
University of Calgary

Clinical Characteristics and Outcomes of Children Potentially Infected by Severe Acute Respiratory Distress Syndrome (SARS)-CoV-2 Presenting to Pediatric Emergency Departments.

Research (Epidemiology) SARS-CoV-2 infection N/A Recruiting
Colorado State University

Oral vaccine Development using genetically-engineered L. acidophilus

Vaccine (Protein Subunit) SARS-CoV-2 spike Unnamed Pre-Clinical
Purdue University

Characterization and sensitive detection of SARS-CoV-2

Research (Modeling) SARS-CoV-2 spike N/A Pre-Clinical
Collaboration: Vir Biotechnology & GSK

Identification of novel SARS CoV2 binding monoclonal antibodies

New Therapies (Antibody-based) SARS-CoV-2 spike VIR-7831 Pre-Clinical
Biocad

mRNA based vaccine development

Vaccine (Nucleic Acid-based) SARS-CoV-2 spike Unnamed Pre-Clinical
Ossianix

Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein

New Therapies (Antibody-based) SARS-CoV-2 spike VNAR antibodies Pre-Clinical
Ziphius Therapeutics

ZIP-1642 consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens, such as a form of the Spike (S) protein, which is an essential protein for host cell infection and has been evaluated as a vaccine antigen for multiple other corona viruses. By using a combination of antigens, Ziphius Therapeutics hopes to elicit a broad and protective immune response.

Vaccine (Nucleic Acid-based) SARS-CoV-2 spike ZIP-1642 Pre-Clinical
Collaboration: Distributed Bio; Centivax; SwiftScale Biologics

Our strategy was to engineer a panel of anti-SARS antibodies to make them recognize and block the novel coronavirus.

New Therapies (Antibody-based) SARS-CoV-2 spike Unnamed Pre-Clinical
Collaboration: Flanders Institute for Biotechnology (VIB); Ghent University

antibody-based drug directed against 2019-nCoV

New Therapies (Antibody-based) SARS-CoV-2 spike Unnamed Pre-Clinical
Regeneron Pharmaceuticals

Novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected

New Therapies (Antibody-based) SARS-CoV-2 spike Pre-Clinical
Collaboration: Los Alamos National Laboratory; Duke Human Vaccine Institute & Department of Surgery; University of Sheffield; Sheffield Teaching Hospitals NHS Foundation Trust; University of Sheffield; Members of Sheffield COVID-19 Genomics Group

Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2

Research (Modeling) SARS-CoV-2 spike N/A Pre-Clinical
Mallinckrodt

iNO’s inhibitory effect on the replication cycle of severe acute respiratory syndrome-related coronavirus (SARS-CoV), and a 2004 study showing improved blood oxygenation, reduced supplemental oxygen, and reduced ventilator support in six SARS-CoV patients treated with iNO.

New Therapies (Small Molecule) SARS-CoV-2 spike INOmax® (nitric oxide) Active, Not Recruiting
Collaboration: Stermirna Therapeutics and Shanghai East Hospital of Tongji University

Chinese news website Yicai.com reported February 10 that the mRNA vaccine being developed by Stermirna Therapeutics and Shanghai East Hospital of Tongji University had begun testing on animals, following approval on an urgent basis in January.

Vaccine (Nucleic Acid-based) SARS-CoV-2 spike Vaccine targeting COVID-19 Pre-Clinical
Synairgen PLC

Interferon beta (IFN-beta) is a naturally occurring protein, which orchestrates the body’s antiviral responses. There is evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility of these at-risk patient groups to developing severe lung disease during respiratory viral infections. Furthermore, viruses, including corona-viruses, have evolved mechanisms which suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune system

SARS-CoV-2 spike SNG001 Phase II
Collaboration: Takis Biotech, Applied DNA Sciences, & Evvivax

Preclinical Development of a DNA-based Vaccine

Vaccine (Nucleic Acid-based) SARS-CoV-2 spike (SARS-Cov-2 S) Unnamed Pre-Clinical
Scancell

Scancell’s DNA vaccines target dendritic cells to stimulate high avidity T-cells that survey and destroy diseased cells

Vaccine (Nucleic Acid-based) SARS-CoV-2 spike + nucleocapsid COVIDITY Pre-Clinical
University of Pittsburgh

Microneedle array to elicit potent anti-SARS-CoV-2 immune response in mice

Vaccine (Protein Subunit) SARS-CoV-2 spike protein PittCoVacc Pre-Clinical
Novavax

Vaccine candidate derived from SARS CoV2 Spike (S) Protein

Vaccine (Protein Subunit) SARS-CoV-2 spike protein NVX-CoV2373 Pre-Clinical
OncoSec

Providence Submits Investigator Initiated IND with CORVax12 for a Phase 1 Clinical Trial

Vaccine (Nucleic Acid-based) SARS-CoV-2 spike protein CORVax12 Phase I
Kleo Pharmaceuticals

Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

New Therapies (Cell-based) SARS-CoV-2 spike protein C19-ARM Pre-Clinical
Thomas Jefferson University

Thomas Jefferson University creates a attenuated viral candidate, CORAVAX

Vaccine (Attenuated) SARS-CoV-2 spike protein CORAVAX Pre-Clinical
Collaboration: FluGen; Bharat Biotech

CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR

Vaccine (Viral Vector) SARS-CoV-2 spike protein CoroFlu Pre-Clinical
Collaboration: Sichuan Clover Biopharmaceuticals; Dynavax

innovative vaccine candidate is based on Clover Biopharmaceutical’s proprietary Trimer-Tag© vaccine technology platform, which is a novel way to produce the spike proteins of the COVID-19 virus in a native trimeric form for use in a vaccine

Vaccine (Protein Subunit) SARS-CoV-2 spike protein COVID-19 S-Trimer Vaccine Pre-Clinical
Molecular Partners

First trispecific anti-COVID-19 therapeutic program: targets three parts of the viral “spike” protein with one drug candidate for broad inhibition of infection and mitigation of future drug resistance

New Therapies (Protein-based) SARS-CoV-2 spike protein Covid-DARPin Pre-Clinical